FMR LLC raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,019,746 shares of the company's stock after acquiring an additional 188,368 shares during the period. FMR LLC owned approximately 5.57% of Denali Therapeutics worth $163,442,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares in the last quarter. KBC Group NV raised its holdings in Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after buying an additional 2,731 shares during the period. AlphaQuest LLC grew its stake in Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after buying an additional 4,449 shares during the period. E Fund Management Co. Ltd. grew its stake in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after buying an additional 2,436 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of Denali Therapeutics by 128.8% in the 4th quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock valued at $224,000 after acquiring an additional 6,195 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts recently weighed in on DNLI shares. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. Bank of America dropped their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 10th. HC Wainwright upped their price target on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, The Goldman Sachs Group reduced their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $37.57.
Get Our Latest Analysis on Denali Therapeutics
Denali Therapeutics Trading Down 0.8 %
NASDAQ DNLI traded down $0.10 during trading hours on Tuesday, reaching $13.17. 1,111,450 shares of the company traded hands, compared to its average volume of 1,081,883. The company has a 50 day moving average of $16.14 and a two-hundred day moving average of $21.60. The stock has a market capitalization of $1.91 billion, a PE ratio of -4.77 and a beta of 1.58. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.
Denali Therapeutics Company Profile
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
See Also
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
